F-18 fluorodeoxyglucose positron emission tomography/computed tomography in conjunctival melanoma with recurrence

Jain, Anurag; John, Arun Ravi; Kishore, Braj; Vishnoi, Madan Gopal; Pandit, Aniruddha; Sharma, Amit; Jaimini, Abhinav; Jain, Mayuri; Singh, Anirudh

doi:10.4103/jcrt.jcrt_453_17

Cited by 1 publication

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…T-cell-directed therapy has met with some success [ 36 ]. The value of FDG PET-CT in the management of conjunctival melanoma is not established, but several case reports suggest that metastatic lesions are hypermetabolic [ 39 , 40 , 41 ].…”

Section: Primary Cutaneous Malignanciesmentioning

confidence: 99%

PET-CT in Clinical Adult Oncology—VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors

Fine

Covington

Koppula

et al. 2022

Cancers

View full text Add to dashboard Cite

PET-CT is an advanced imaging modality with many oncologic applications, including staging, therapeutic assessment, restaging and surveillance for recurrence. The goal of this series of six review articles is to provide practical information to providers and imaging professionals regarding the best use of PET-CT for specific oncologic indications, the potential pitfalls and nuances that characterize these applications, and guidelines for image interpretation. Tumor-specific clinical information and representative PET-CT images are provided. The current, sixth article in this series addresses PET-CT in an evaluation of aggressive cutaneous malignancies, sarcomas and neuroendocrine tumors. A discussion of the role of FDG PET for all types of tumors in these categories is beyond the scope of this review. Rather, this article focuses on the most common malignancies in adult patients encountered in clinical practice. It also focuses on Food and Drug Agency (FDA)-approved and clinically available radiopharmaceuticals rather than research tracers or those requiring a local cyclotron. This information will serve as a guide to primary providers for the appropriate role of PET-CT in managing patients with cutaneous malignancies, sarcomas and neuroendocrine tumors. The nuances of PET-CT interpretation as a practical guide for imaging providers, including radiologists, nuclear medicine physicians and their trainees, are also addressed.

show abstract